Related Experiment Video

Updated: Jun 20, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics

G Halldén1

  • 1Centre for Molecular Oncology and Imaging, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. g.hallden@qmul.ac.uk

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|September 29, 2009
PubMed

Insights

Novel oncolytic adenoviruses, engineered with specific gene deletions, enhance cancer cell killing when combined with chemotherapy. This dual therapy shows promise for treating solid tumors, potentially allowing for reduced chemotherapy doses.

Area of Science:

  • Oncology
  • Virology
  • Gene Therapy

Background:

  • Replication-selective oncolytic adenoviruses show promise as anti-tumor agents, with improved efficacy when combined with chemotherapeutics.
  • Further development requires understanding cellular mechanisms of enhanced tumor elimination and creating more potent viral mutants.

Purpose of the Study:

  • To generate and evaluate novel adenoviral mutants with deletions in anti-apoptotic (E1B19K) and pRb-binding (E1ACR2) genes.
  • To assess the efficacy of these mutants, particularly a double-deleted mutant (AdDeltaDelta), in combination with cytotoxic drugs against solid tumors.

Main Methods:

  • Generation of adenoviral mutants with E1B19K gene deletion and/or E1ACR2 region deletion.
  • Evaluation of tumor cell killing in vitro and in vivo (prostate and pancreatic carcinoma models) with and without chemotherapeutics (gemcitabine, 5-FU, docetaxel, mitoxantrone).
  • Assessment of viral replication in tumor and normal cells.

Main Results:

  • E1B19K-deleted mutants enhanced drug-induced apoptosis and tumor cell killing without sensitizing normal cells.
  • The AdDeltaDelta mutant demonstrated high cell killing activity and synergistic enhancement of cell death with chemotherapeutics in vitro and in vivo.
  • AdDeltaDelta showed similar replication to parental viruses in tumor cells but was attenuated in normal cells.

Conclusions:

  • The AdDeltaDelta mutant shows significant potential as a therapeutic agent for solid tumors, especially when used in combination with cytotoxic chemotherapy.
  • This combination therapy may allow for the use of lower, less toxic doses of chemotherapy in clinical settings.
  • AdDeltaDelta represents a promising candidate for enhancing oncolytic virotherapy efficacy against adenocarcinomas.

More Related Videos

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...